Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies

L Gossec; TK Kvien; PG Conaghan; M Østergaard; D Gladman; P Mease; L Rasouliyan; L Pricop; C Gaillez; S Jugl

doi:10.1136/annrheumdis-2017-eular.1719

Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies

L Gossec, TK Kvien, PG Conaghan, M Østergaard, D Gladman, P Mease, L Rasouliyan, L Pricop, C Gaillez, S Jugl

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	SAT0463
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	76
Udgave nummer	Suppl 2
Sider (fra-til)	949
ISSN	0003-4967
DOI	https://doi.org/10.1136/annrheumdis-2017-eular.1719
Status	Udgivet - 2017

Adgang til dokumentet

10.1136/annrheumdis-2017-eular.1719

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Gossec, L., Kvien, TK., Conaghan, PG., Østergaard, M., Gladman, D., Mease, P., Rasouliyan, L., Pricop, L., Gaillez, C., & Jugl, S. (2017). Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies. Annals of the Rheumatic Diseases, 76(Suppl 2), 949. Artikel SAT0463 . https://doi.org/10.1136/annrheumdis-2017-eular.1719

Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies. / Gossec, L; Kvien, TK; Conaghan, PG et al.
I: Annals of the Rheumatic Diseases, Bind 76, Nr. Suppl 2, SAT0463 , 2017, s. 949.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Gossec, L, Kvien, TK, Conaghan, PG, Østergaard, M, Gladman, D, Mease, P, Rasouliyan, L, Pricop, L, Gaillez, C & Jugl, S 2017, 'Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies', Annals of the Rheumatic Diseases, bind 76, nr. Suppl 2, SAT0463 , s. 949. https://doi.org/10.1136/annrheumdis-2017-eular.1719

@article{1fc8806244834b279e2f6dbebb24eedd,

title = "Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies",

author = "L Gossec and TK Kvien and PG Conaghan and M {\O}stergaard and D Gladman and P Mease and L Rasouliyan and L Pricop and C Gaillez and S Jugl",

year = "2017",

doi = "10.1136/annrheumdis-2017-eular.1719",

language = "English",

volume = "76",

pages = "949",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "Suppl 2",

}

TY - ABST

T1 - Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years

T2 - long-term data from the future 1 and future 2 studies

AU - Gossec, L

AU - Kvien, TK

AU - Conaghan, PG

AU - Østergaard, M

AU - Gladman, D

AU - Mease, P

AU - Rasouliyan, L

AU - Pricop, L

AU - Gaillez, C

AU - Jugl, S

PY - 2017

Y1 - 2017

U2 - 10.1136/annrheumdis-2017-eular.1719

DO - 10.1136/annrheumdis-2017-eular.1719

M3 - Conference abstract in journal

SN - 0003-4967

VL - 76

SP - 949

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

M1 - SAT0463

ER -